Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
Louis MeyblumCéline ChevaleyreSandrine SusiniBenoit JegoFrederic DeschampsDimitri KereselidzeBaptiste BonnetAurélien MarabelleThierry de BaereVincent LebonLambros TselikasCharles TruilletPublished in: Journal for immunotherapy of cancer (2023)
ImmunoPET-derived pharmacokinetics supports intratumoral injection of ICBs to decrease systemic exposure while maintaining efficacy compared with intravenous. Intratumoral-ICBs lead to high local drug exposure while maintaining significant therapeutic exposure in non-injected tumors. This immunoPET approach is applicable for clinical practice to support evidence-based drug development.